Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure

被引:102
作者
Mathew, J
Hunsberger, S
Fleg, J
Mc Sherry, F
Williford, W
Yusuf, S
机构
[1] Univ Iowa, Coll Med, Dept Med, Iowa City, IA 52242 USA
[2] Galesburg Cottage Hosp, Dept Cardiol, Galesburg, IL 61401 USA
[3] LaSalle Cardiol, Galesburg, IL USA
[4] NHLBI, NIH, Bethesda, MD 20892 USA
[5] Johns Hopkins Bayview Med Ctr, Div Cardiol, Baltimore, MD USA
[6] Vet Affairs Med Ctr, Perry Point, MD USA
[7] McMaster Univ, Div Cardiol, Hamilton, ON, Canada
关键词
atrial fibrillation; congestive heart failure; digoxin; stroke; supraventricular arrhythmia;
D O I
10.1378/chest.118.4.914
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: The incidence, predictive factors, morbidity, and mortality associated with the development of supraventricular tachyarrhythmias (SVTs) in patients with congestive heart failure (CHF) are poorly defined, Methods: In the Digitalis Investigation Group trial, patients with CHF who were in sinus rhythm were randomly assigned to digoxin (n = 3,889) or placebo (n = 3,899) and followed up for a mean of 37 months, Baseline factors that predicted the occurrence of SVT and the effects of SVT on total mortality, stroke, and hospitalization for worsening CHF were determined. Results: Eight hundred sixty-six patients (11.1%) had SVT during the study period. Older age (odds ratio [OR], 1.029 for each year increase in age; p = 0.0001), male sex (OR, 1.270; p = 0.0075), increasing duration of CHF (OR, 1.003 for each month increase in duration of CHF; p = 0.0021), and a cardiothoracic ratio of > 0.50 (OR, 1.403; p = 0.0001) predicted an increased risk of experiencing SVT, Left ventricular ejection fraction, New York Heart Association functional class, and treatment with digoxin vs placebo were not related to the occurrence of SVT. After adjustment for other risk factors, development of SVT predicted a greater risk of subsequent total mortality (risk ratio [RR] = 2.451; p = 0.0001), stroke (RR = 2.352; p = 0.0001), and hospitalization for worsening CHF (RR = 3.004; p = 0.0001). Conclusion: In CHF patients in sinus rhythm, older age, male sex, longer duration of CHF, and increased cardiothoracic ratio predict an increased risk for experiencing SVT. Development of SVT is a strong independent predictor of mortality, stroke, and hospitalization for CHF in this population. Prevention of SVT may prolong survival and reduce morbidity in CHF patients.
引用
收藏
页码:914 / 922
页数:9
相关论文
共 27 条
[1]  
Abernathy GT, 1996, CONTROL CLIN TRIALS, V17, P77
[2]  
ANTMAN E, 1993, J AM COLL CARDIOL, V22, P1830
[3]   Impact of atrial fibrillation on the risk of death [J].
Benjamin, EJ ;
Wolf, PA ;
D'Agostino, RB ;
Silbershatz, H ;
Kannel, WB ;
Levy, D .
CIRCULATION, 1998, 98 (10) :946-952
[4]   INDEPENDENT RISK-FACTORS FOR ATRIAL-FIBRILLATION IN A POPULATION-BASED COHORT - THE FRAMINGHAM HEART-STUDY [J].
BENJAMIN, EJ ;
LEVY, D ;
VAZIRI, SM ;
DAGOSTINO, RB ;
BELANGER, AJ ;
WOLF, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (11) :840-844
[5]  
CARSON PE, 1993, CIRCULATION, V87, P102
[6]   CANADIAN ATRIAL-FIBRILLATION ANTICOAGULATION (CAFA) STUDY [J].
CONNOLLY, SJ ;
LAUPACIS, A ;
GENT, M ;
ROBERTS, RS ;
CAIRNS, JA ;
JOYNER, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (02) :349-355
[7]   EFFICACY AND SAFETY OF QUINIDINE THERAPY FOR MAINTENANCE OF SINUS RHYTHM AFTER CARDIOVERSION - A METAANALYSIS OF RANDOMIZED CONTROL TRIALS [J].
COPLEN, SE ;
ANTMAN, EM ;
BERLIN, JA ;
HEWITT, P ;
CHALMERS, TC .
CIRCULATION, 1990, 82 (04) :1106-1116
[8]   Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials [J].
Dries, DL ;
Exner, DV ;
Gersh, BJ ;
Domanski, MJ ;
Waclawiw, MA ;
Stevenson, LW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (03) :695-703
[9]   WARFARIN IN THE PREVENTION OF STROKE ASSOCIATED WITH NONRHEUMATIC ATRIAL-FIBRILLATION [J].
EZEKOWITZ, MD ;
BRIDGERS, SL ;
JAMES, KE ;
CARLINER, NH ;
COLLING, CL ;
GORNICK, CC ;
KRAUSESTEINRAUF, H ;
KURTZKE, JF ;
NAZARIAN, SM ;
RADFORD, MJ ;
RICKLES, FR ;
SHABETAI, R ;
DEYKIN, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (20) :1406-1412
[10]   ANTIARRHYTHMIC DRUG-THERAPY AND CARDIAC MORTALITY IN ATRIAL-FIBRILLATION [J].
FLAKER, GC ;
BLACKSHEAR, JL ;
MCBRIDE, R ;
KRONMAL, RA ;
HALPERIN, JL ;
HART, RG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 20 (03) :527-532